21:43 , Oct 26, 2018 |  BioCentury  |  Finance

Springing into Cerevel

Bain Capital is following the blueprint for Pfizer Inc. (NYSE:PFE) spinout SpringWorks Therapeutics LLC and applying it on a larger scale to Cerevel Therapeutics LLC, which will develop Pfizer’s discontinued neuroscience pipeline with $350 million...
19:39 , Oct 26, 2018 |  BC Week In Review  |  Financial News

Pfizer neuroscience spinout Cerevel launches with $350M from Bain

Less than a year after terminating its neuroscience program, Pfizer Inc. (NYSE:PFE) spun out Cerevel Therapeutics LLC with $350 million in funding from Bain Capital. The pharma will have a 25% stake in Cerevel, which...
19:11 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Lundbeck’s Lu AF35700 misses schizophrenia endpoint

The first Phase III trial from H. Lundbeck A/S (CSE:LUN) to read out since CEO Deborah Dunsire took the helm last month has missed its primary endpoint. Lundbeck reported that Lu AF35700 missed the primary...
23:01 , Oct 25, 2018 |  BC Extra  |  Clinical News

Lundbeck’s Lu AF35700 misses schizophrenia endpoint

The first Phase III trial from H. Lundbeck A/S (CSE:LUN) to read out since CEO Deborah Dunsire took the helm last month has missed its primary endpoint. Lundbeck slid DKK108.90 (27%) to DKK300 on Thursday...
21:49 , Oct 23, 2018 |  BC Extra  |  Company News

Pfizer neuroscience spinout Cerevel launches with $350M from Bain

Less than a year after terminating its neuroscience program, Pfizer Inc. (NYSE:PFE) spun out Cerevel Therapeutics LLC with $350 million in funding from Bain Capital. The pharma will have a 25% stake in Cerevel, which...